Export

You can select particular sections to be included in the output file.

Model List of Essential Medicines

Found 1311 recommendations for 634 medicines and 143 therapeutic equivalents
Removed medicines and rejected applications are not shown. Show them.
  1. BCG vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  2. Japanese encephalitis vaccine General information
    Section
    Recommendations for certain regions
    • All vaccines should comply with the WHO requirements for biological substances.
  3. Medicines for COVID-19 General information
    Section
    Medicines for COVID-19
    • Refer to WHO living guidelines
    Indications
  4. Abacavir General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (as sulfate)
  5. Abacavir + lamivudine General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)
  6. Abiraterone General information
    Section
    Hormones and antihormones
    • Oral > Solid: 250 mg; 500 mg
  7. Acamprosate calcium General information
    Section
    Medicines for alcohol use disorders
    • Oral > Solid > tablet: 333 mg
  8. Acetazolamide General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Oral > Solid: 250 mg
  9. Acetic acid General information
    Section
    Ear, nose and throat medicines [c]
    • Local > Otological > drops: 2% in alcohol
  10. Acetylcysteine General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule
    • Oral > Liquid: 10%; 20%
  11. Acetylsalicylic acid General information
    Section
    Antimigraine medicines > For treatment of acute attack
    • Oral > Solid: 300 to 500 mg
    Indications
    Section
    Anti-platelet medicines
    • Oral > Solid: 100 mg
    Section
    Medicines for juvenile joint diseases
    • Oral > Solid: 100 to 500 mg
    • Local > Rectal > Suppository: 50 to 150 mg
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Solid: 100 to 500 mg
    • Local > Rectal > Suppository: 50 to 150 mg
    Indications
  12. Acetylsalicylic acid + atorvastatin + ramipril General information
    Section
    Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease
    • Oral > Solid > tablet: 100 mg + 20 mg + 2.5 mg; 100 mg + 20 mg + 5 mg; 100 mg + 20 mg + 10 mg; 100 mg + 40 mg + 2.5 mg; 100 mg + 40 mg + 5 mg; 100 mg + 40 mg + 10 mg
  13. Acetylsalicylic acid + simvastatin + ramipril + atenolol + hydrochlorothiazide General information
    Section
    Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease
    • Oral > Solid > tablet: 100 mg + 20 mg + 5 mg + 50 mg + 12.5 mg
  14. Aciclovir General information
    Section
    Antiherpes medicines
    • Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt)
    • Oral > Liquid: 200 mg per 5 mL
    • Oral > Solid: 200 mg tablet
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 3% w/w
  15. Aclidinium General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
  16. Activated charcoal General information
    Section
    Antidotes and other substances used in poisonings > Non-specific
    • Oral > Other: powder
  17. Adalimumab General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
    Section
    Medicines for juvenile joint diseases
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
  18. Afatinib General information
    Section
    Targeted therapies
  19. Albendazole General information
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 400 mg (chewable, scored))
    • Oral > Solid > tablet: 400 mg (chewable, scored)
    Section
    Antifilarials
    • Oral > Solid > tablet: 400 mg (chewable, scored)
    Indications
    Section
    Cysticidal medicines
    • Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)
  20. Alcohol based hand rub General information
    Section
    Disinfectants
    • Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol
  21. All-trans retinoic acid General information
    Section
    Targeted therapies
    • Oral > Solid: 10 mg capsule
  22. Allopurinol General information
    Section
    Medicines used to treat gout
    • Oral > Solid: 100 mg
    Indications
    Section
    Supportive medicines
    • Oral > Solid: 100 mg; 300 mg
  23. Alteplase General information
    Section
    Thrombolytic medicines
    • Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection
  24. Amidotrizoate General information
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > unspecified: 140 to 420 mg iodine per mL in 20 mL ampoule (as sodium or meglumine salt)
    Indications
  25. Amikacin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin for Other specified conjunctivitis Therapeutic equivalent to gentamicin for Infectious blepharitis
    Section
    Antituberculosis medicines
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)
  26. Amiloride General information
    Section
    Diuretics
    • Oral > Solid: 5 mg (hydrochloride)
  27. Amiodarone General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 50 mg per mL in 3 ampoule (hydrochloride)
    • Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride)
  28. Amitriptyline General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 25 mg; 10 mg; 75 mg
    Indications
    Section
    Medicines for depressive disorders
    • Oral > Solid: 25 mg; 75 mg
  29. Amlodipine General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 5 mg (as maleate, mesylate or besylate)
  30. Amodiaquine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)
  31. Amodiaquine + sulfadoxine + pyrimethamine General information
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package
    Indications
  32. Amoxicillin General information
    Section
    Access group antibiotics
    • Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)
    • Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
    • Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
    • Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)
    • Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)
  33. Amoxicillin + clavulanic acid General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
    • Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)
    • Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) powder for oral liquid
    • Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
    • Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
    • Oral > Liquid: 125 mg + 31.25 mg powder for oral liquid; 250 mg + 62.5 mg powder for oral liquid
    Section
    Antituberculosis medicines
    • Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg per 5 mL (as potassium salt) powder for oral liquid
    • Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)
  34. Amphotericin B General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)
  35. Ampicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
  36. Anastrozole General information
    Section
    Hormones and antihormones
    • Oral > Solid: 1 mg tablet
    Section
    Ovulation inducers
  37. Anidulafungin General information
    Section
    Antifungal medicines
    Indications
  38. Ansuvimab General information
    Section
    Medicines for Ebola virus disease
    • Parenteral > General injections > IV: 400 mg powder for injection
  39. Anti-d immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IV: 250 µg in single-dose vial
    • Parenteral > General injections > IM: 250 µg in single-dose vial
  40. Anti-rabies immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IM: 150 IU per mL in vial
    • Parenteral > Locoregional injections > Other: 150 IU per mL in vial
    Indications
  41. Anti-rabies virus monoclonal antibodies General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > Locoregional injections > Intradermal: 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine)
    Indications
  42. Anti-tetanus immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IM: 500 IU in vial
    Indications
  43. Antivenom immunoglobulin General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IV:
  44. Apixaban General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation
  45. Aprepitant General information
    Section
    Antiemetic medicines
    • Oral > Liquid: 125 mg powder for oral suspension (in sachet)
    • Oral > Solid: 80 mg; 125 mg; 165 mg
  46. Aripiprazole General information
    Section
    Medicines for bipolar disorders
    Indications
    Therapeutic equivalent to quetiapine for Bipolar or related disorders
    Section
    Medicines for psychotic disorders
  47. Arsenic trioxide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion
  48. Artemether General information
    Section
    Antimalarial medicines > For curative treatment
    • Parenteral > General injections > IM: 80 mg per mL in 1 mL ampoule (oily injection)
  49. Artemether + lumefantrine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet
  50. Artesunate General information
    Section
    Antimalarial medicines > For curative treatment
    • Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution
    • Oral > Solid: 50 mg tablet
    • Local > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules
  51. Artesunate + amodiaquine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet
  52. Artesunate + mefloquine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet
  53. Artesunate + pyronaridine tetraphosphate General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules
  54. Ascorbic acid General information
    Section
    Vitamins and minerals
    • Oral > Solid: 50 mg
    Indications
  55. Asparaginase General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
  56. Atazanavir + ritonavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)
  57. Atenolol General information
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to bisoprolol for Essential hypertension
  58. Atoltivimab + maftivimab + odesivimab General information
    Section
    Medicines for Ebola virus disease
    • Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial
  59. Atorvastatin General information
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis
  60. Atorvastatin + perindopril + amlodipine General information
    Section
    Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease
    • Oral > Solid > tablet: 20 mg + 5 mg + 5 mg; 20 mg + 10 mg + 10 mg; 40 mg + 5 mg + 5 mg; 40 mg + 10 mg + 10 mg
  61. Atracurium General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 10 mg per mL (besylate)
    Indications
  62. Atropine General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)
    Section
    Diagnostic agents > Ophthalmic medicines
    Indications
    Therapeutic equivalent to tropicamide for Cycloplegic drug
    Section
    Ophthalmological preparations > Mydriatics
    • Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)
    Indications
  63. Azathioprine General information
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 50 mg
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt); 50 mg in vial powder for injection (as sodium salt)
    • Oral > Liquid: 10 mg per mL
    • Oral > Solid > tablet: 50 mg (scored); 25 mg
  64. Azithromycin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 1.5% eye drops
    Indications
    Section
    Watch group antibiotics
    • Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)
    • Oral > Liquid: 200 mg per 5 mL oral liquid
    • Oral > Solid: 250 mg (anhydrous) capsule; 500 mg (anhydrous) capsule
  65. Barium sulfate General information
    Section
    Diagnostic agents > Radiocontrast media
    • Oral > Liquid: Aqueous suspension
  66. Beclometasone General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide for Asthma
  67. Beclometasone + formoterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol for Asthma
  68. Bedaquiline General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 100 mg tablet; 20 mg tablet
  69. Bendamustine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL
  70. Benzathine benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU)
  71. Benznidazole General information
    Section
    American trypanosomiasis
    • Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg
    Indications
  72. Benzoyl peroxide General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Cream: 5%
    • Local > Topical > Lotion: 5%
    Indications
  73. Benzyl benzoate General information
    Section
    Dermatological medicines > Scabicides and pediculicides
    • Local > Topical > Lotion: 25%
  74. Benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
  75. Betamethasone General information
    Section
    Dermatological medicines > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Cream: 0.1% (as valerate)
    • Local > Topical > Ointment: 0.1% (as valerate)
  76. Bevacizumab General information
    Section
    Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations
    • Parenteral > Locoregional injections > Intravitreal: 25 mg per mL
  77. Bicalutamide General information
    Section
    Hormones and antihormones
    • Oral > Solid: 50 mg
  78. Biperiden General information
    Section
    Medicines for parkinsonism
    • Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate)
    • Oral > Solid: 2 mg tablet (hydrochloride)
  79. Bisacodyl General information
    Section
    Laxatives
    Indications
    Therapeutic equivalent to senna for Constipation
  80. Bisoprolol General information
    Section
    Antianginal medicines
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Section
    Medicines used in heart failure
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Section
    Antiarrhythmic medicines
    • Oral > Solid: 1.25 mg; 5 mg
    Section
    Antihypertensive medicines
    • Oral > Solid: 1.25 mg; 5 mg
  81. Bleomycin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)
  82. Bortezomib General information
    Section
    Targeted therapies
    • Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
  83. Bromocriptine General information
    Section
    Medicines for disorders of the pituitary hormone system
  84. Budesonide General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > aerosol: 100 µg per dose; 200 µg per dose
    Indications
    Section
    Ear, nose and throat medicines [c]
    • Local > Nasal > Spray: 100 µg per dose
  85. Budesonide + formoterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > dry powder: 100 µg + 6 µg per dose; 200 µg + 6 µg per dose
    Indications
  86. Budesonide + salmeterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol for Asthma
  87. Bumetanide General information
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to furosemide for Heart failure
    Section
    Diuretics
    Indications
    Therapeutic equivalent to furosemide for Anuria or oliguria Therapeutic equivalent to furosemide for Oedema
  88. Bupivacaine General information
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 7.5% glucose solution
    • Parenteral > General injections > unspecified: 0.25% in vial (hydrochloride); 0.5% in vial (hydrochloride)
  89. Buprenorphine General information
    Section
    Medicines for disorders due to psychoactive substance use
    Indications
    Therapeutic equivalent to methadone for Opioid dependence
  90. Bupropion General information
    Section
    Medicines for disorders due to psychoactive substance use
    • Oral > Solid: 150 mg sustained-release (hydrochloride)
  91. Cabergoline General information
    Section
    Medicines for disorders of the pituitary hormone system
    • Oral > Solid > tablet: 0.5 mg; 1 mg
  92. Caffeine citrate General information
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
    • Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
  93. Calamine General information
    Section
    Dermatological medicines > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Lotion:
    Indications
  94. Calcipotriol General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Cream: 50 µg per mL (0.005%)
    • Local > Topical > Lotion: 50 µg per mL (0.005%)
    • Local > Topical > Ointment: 50 µg per mL (0.005%)
  95. Calcitriol General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
  96. Calcium General information
    Section
    Vitamins and minerals
    • Oral > Solid: 500 mg (elemental calcium)
  97. Calcium folinate (leucovorin calcium) General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
    • Oral > Solid > tablet: 15 mg; 5 mg; 25 mg
  98. Calcium gluconate General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Section
    Vitamins and minerals
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
  99. Canagliflozin General information
    Section
    Oral hypoglycaemic agents
    Indications
    Therapeutic equivalent to empagliflozin for Type 2 diabetes mellitus
  100. Carbachol General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    Indications
  101. Carbamazepine General information
    Section
    Antiseizure medicines
    • Oral > Liquid: 100 mg per 5 mL
    • Oral > Solid > tablet: 200 mg (scored); 100 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)
    Section
    Medicines for bipolar disorders
    • Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 400 mg
  102. Carbetocin General information
    Section
    Uterotonics
    • Parenteral > General injections > IV: 100 µg per mL (heat stable)
  103. Carbimazole General information
    Section
    Thyroid hormones and antithyroid medicines
    Indications
    Therapeutic equivalent to methimazole for Thyrotoxicosis
  104. Carvedilol General information
    Section
    Antianginal medicines
    Indications
    Therapeutic equivalent to bisoprolol for Angina pectoris
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to bisoprolol for Heart failure
    Section
    Antiarrhythmic medicines
    Indications
    Therapeutic equivalent to bisoprolol for Cardiac arrhythmia
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to bisoprolol for Essential hypertension
  105. Caspofungin General information
    Section
    Antifungal medicines
    Indications
  106. Cefalexin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)
    • Oral > Solid > dispersible tablet: 125 mg; 250 mg
  107. Cefazolin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection
  108. Cefiderocol General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection
  109. Cefixime General information
    Section
    Watch group antibiotics
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)
  110. Cefotaxime General information
  111. Ceftazidime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection
    Indications
    First choice
    co-prescribed with vancomycin Endophthalmitis
    Other indications
  112. Ceftazidime + avibactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection
  113. Ceftolozane + tazobactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g + 0.5 g powder for injection
  114. Ceftriaxone General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 2 g in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
  115. Cefuroxime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection
    Indications
  116. Certolizumab pegol General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Rheumatoid arthritis Therapeutic equivalent to adalimumab for Crohn disease site
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
  117. Cetirizine General information
    Section
    Antiallergics and medicines used in anaphylaxis
  118. Chlorambucil General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 2 mg tablet
  119. Chloramphenicol General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
    • Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
    Indications
  120. Chlorhexidine General information
    Section
    Medicines administered to the neonate [c]
    • Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
    • Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
    Section
    Antiseptics
    • Local > Topical > Solution: 5% (digluconate) for dilution
    Indications
  121. Chlorine base compound General information
    Section
    Disinfectants
    • Local > Topical > Powder: 0.1% available chlorine for solution
    • Local > Topical > Liquid: 0.1% available chlorine for solution
    • Local > Topical > Solid: 0.1% available chlorine for solution
  122. Chloroquine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
    • Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
    • Oral > Solid: 150 mg tablet (as phosphate or sulfate)
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)
  123. Chlorothiazide General information
    Section
    Antihypertensive medicines
    Indications
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to hydrochlorothiazide for Heart failure
  124. Chloroxylenol General information
    Section
    Disinfectants
    • Local > Topical > Solution: 4.8%
  125. Chlorpromazine General information
    Section
    Medicines for psychotic disorders
    • Oral > Liquid: 25 mg per 5 mL (hydrochloride)
    • Oral > Solid: 100 mg (hydrochloride)
  126. Chlortalidone General information
    Section
    Antihypertensive medicines
    Indications
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to hydrochlorothiazide for Heart failure
  127. Chlortetracycline General information
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to tetracycline for Other specified conjunctivitis Therapeutic equivalent to tetracycline for Infectious keratitis Therapeutic equivalent to tetracycline for Trachoma Therapeutic equivalent to tetracycline for Infectious blepharitis
  128. Cholera vaccine General information
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
  129. Ciclesonide General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide for Asthma
  130. Ciclosporin General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection
    • Oral > Liquid: 100 mg per mL
    • Oral > Solid > capsule: 25 mg
  131. Ciprofloxacin General information
    Section
    Watch group antibiotics
    • Oral > Solid: 250 mg (as hydrochloride); 500 mg (as hydrochloride)
    • Parenteral > General injections > IV: 2 mg per mL (as hyclate)
    • Oral > Liquid: 250 mg per 5 mL (anhydrous)
    • Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)
    Section
    Ear, nose and throat medicines [c]
    • Local > Otological > drops: 0.3% (as hydrochloride)
  132. Citalopram General information
    Section
    Medicines for anxiety disorders
    Indications
    Therapeutic equivalent to fluoxetine for Social anxiety disorder Therapeutic equivalent to fluoxetine for Panic disorder Therapeutic equivalent to fluoxetine for Generalised anxiety disorder
    Section
    Medicines for obsessive compulsive disorders
    Indications
    Therapeutic equivalent to fluoxetine for Obsessive-compulsive disorder
    Section
    Medicines for depressive disorders
    Indications
    Therapeutic equivalent to fluoxetine for Depressive disorders
  133. Cladribine General information
    Section
    Medicines for multiple sclerosis
    • Oral > Solid > tablet: 10 mg
  134. Clarithromycin General information
    Section
    Watch group antibiotics
    • Oral > Solid: 500 mg
    • Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection
    • Oral > Solid > dosage form: 500 mg; 250 mg
  135. Clindamycin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)
    • Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)
    • Oral > Solid: 150 mg (as hydrochloride)
  136. Clofazimine General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 100 mg; 50 mg
    Section
    Antileprosy medicines
    • Oral > Solid: 100 mg; 50 mg
    Indications
  137. Clomifene General information
    Section
    Ovulation inducers
    • Oral > Solid: 50 mg (citrate)
  138. Clomipramine General information
    Section
    Medicines for obsessive compulsive disorders
    • Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)
  139. Clopidogrel General information
    Section
    Anti-platelet medicines
    • Oral > Solid: 75 mg; 300 mg
  140. Clotrimazole General information
    Section
    Antifungal medicines
    • Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet
  141. Cloxacillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection
    • Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)
  142. Clozapine General information
    Section
    Medicines for psychotic disorders
    • Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg
  143. Coagulation factor IX General information
    Section
    Blood coagulation factors
    • Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection
  144. Coagulation factor IX complex General information
    Section
    Blood coagulation factors
  145. Coagulation factor VIII General information
    Section
    Blood coagulation factors
    • Parenteral > General injections > IV: 500 IU in vial powder for injection; 250 IU in vial powder for injection; 1000 IU in vial powder for injection
    Indications
  146. Coal tar General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Solution: 5%
  147. Codeine General information
    Section
    Opioid analgesics
    • Oral > Solid: 30 mg tablet (codeine phosphate)
    Indications
  148. Colecalciferol General information
    Section
    Vitamins and minerals
    • Oral > Liquid: 400 IU per mL
    • Oral > Solid: 400 IU; 1000 IU
  149. Colistin (injection) General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) (equivalent to 34 mg colistin base activity)
  150. Compound sodium lactate solution General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: injectable solution
  151. Copper-containing intrauterine device General information
  152. Cryoprecipitate (pathogen-reduced) General information
    Section
    Blood and blood components
    • Injection: frozen liquid in bag or lyophilized powder in vial containing:
    • > 50 IU Factor VIII
    • > 100 IU vWF
    • > 140 mg clottable fibrinogen per unit
  153. Cyclizine General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 50 mg tablet
    • Parenteral > General injections > unspecified: 50 mg per mL
    Indications
  154. Cyclopentolate General information
    Section
    Diagnostic agents > Ophthalmic medicines
    Indications
    Therapeutic equivalent to tropicamide for Cycloplegic drug
    Section
    Ophthalmological preparations > Mydriatics
    Indications
    Therapeutic equivalent to atropine for Anterior uveitis
  155. Cyclophosphamide General information
  156. Cycloserine General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 250 mg; 125 mg
  157. Dabigatran General information
    Section
    Medicines affecting coagulation
    • Oral > Solid: 110 mg; 150 mg
  158. Dacarbazine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection
    Indications
  159. Daclatasvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 30 mg tablet (as hydrochloride); 60 mg tablet (as hydrochloride)
  160. Daclatasvir + sofosbuvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 60 mg + 400 mg
  161. Dalteparin General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin for Acute ischaemic heart disease Therapeutic equivalent to enoxaparin for Venous thromboembolism
  162. Dapagliflozin General information
    Section
    Oral hypoglycaemic agents
    Indications
    Therapeutic equivalent to empagliflozin for Type 2 diabetes mellitus
  163. Dapsone General information
    Section
    Antileprosy medicines
    • Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet
    Indications
  164. Darbepoetin alfa General information
    Section
    Antianaemia medicines
  165. Darunavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg
  166. Dasatinib General information
    Section
    Targeted therapies
    • Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet
  167. Daunorubicin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)
  168. Deferasirox General information
    Section
    Other medicines for haemoglobinopathies
    • Oral > Solid > dispersible tablet: 100 mg; 125 mg; 250 mg; 400 mg; 500 mg
    • Oral > Solid > tablet: 90 mg; 180 mg; 360 mg
  169. Deferiprone General information
    Section
    Other medicines for haemoglobinopathies
  170. Deferoxamine General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
    Section
    Other medicines for haemoglobinopathies
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
  171. Delamanid General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 50 mg tablet; 25 mg tablet (dispersible)
  172. Dengue vaccine General information
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
  173. Desmopressin General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)
    • Local > Nasal > Spray: 10 µg per dose (acetate)
  174. Dexamethasone General information
    Section
    Other medicines administered to the mother
    • Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))
    Section
    Hormones and antihormones
    • Oral > Solid: 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 2 mg; 4 mg
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 2 mg; 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
    Indications
    Section
    Antiallergics and medicines used in anaphylaxis
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
    Section
    Antiemetic medicines
    • Oral > Liquid: 0.5 mg per 5 mL; 2 mg per 5 mL
    • Oral > Solid: 0.5 mg; 0.75 mg; 1.5 mg; 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
  175. Dextran 70 General information
    Section
    Plasma substitutes
    • Parenteral > General injections > IV: 6% injectable solution
    Indications
  176. Diazepam General information
    Section
    Antiseizure medicines
    • Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system
    • Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube
    Indications
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 5 mg; 10 mg
    • Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system
    • Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube
    • Parenteral > General injections > unspecified: 5 mg per mL
    Indications
    Section
    Medicines for anxiety disorders
    • Oral > Solid: 5 mg (scored); 2 mg (scored)
    Indications
  177. Diazoxide General information
    Section
    Medicines for hypoglycaemia
    • Oral > Liquid: 50 mg per mL
    • Oral > Solid: 50 mg
  178. Diethylcarbamazine General information
    Section
    Antifilarials
    • Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)
  179. Digoxin General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule
    • Oral > Liquid: 50 µg per mL
    • Oral > Solid: 62.5 µg; 250 µg
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule; 100 µg per mL in 1 mL ampoule
    • Oral > Liquid: 50 µg per mL
    • Oral > Solid > tablet: 62.5 µg; 250 µg; 125 µg
    Indications
  180. Dihydroartemisinin + piperaquine phosphate General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet
  181. Diloxanide General information
    Section
    Antiamoebic and antigiardiasis medicines
    • Oral > Solid: 500 mg (furoate)
    Indications
  182. Dimercaprol General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule
  183. Diphtheria antitoxin General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial
  184. Diphtheria vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  185. Docetaxel General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL
  186. Docusate sodium General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 50 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg capsule
    Indications
  187. Dolasetron General information
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron for Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron for Nausea or vomiting
  188. Dolutegravir General information
    Section
    Antiretrovirals > Integrase inhibitors
    • Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)
  189. Dolutegravir + lamivudine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
  190. Dopamine General information
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 40 mg per mL in 5 mL vial (hydrochloride)
  191. Doxorubicin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
    • Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)
  192. Doxorubicin (as pegylated liposomal) General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
  193. Doxycycline General information
    Section
    Access group antibiotics
    • Oral > Solid: 100 mg (as hyclate)
    • Parenteral > General injections > unspecified: 100 mg in vial powder for injection
    • Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)
    • Oral > Solid: 50 mg (as hyclate); 100 mg (as hyclate)
    • Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 100 mg (hydrochloride or hyclate)
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)
  194. Edoxaban General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation
  195. Efavirenz General information
    Section
    Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
    • Oral > Solid: 600 mg tablet
  196. Efavirenz + emtricitabine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
  197. Efavirenz + lamivudine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)
  198. Eflornithine General information
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Parenteral > General injections > IV: 200 mg per mL in 50 mL bottle (hydrochloride)
  199. Empagliflozin General information
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 10 mg; 25 mg
  200. Emtricitabine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
  201. Enalapril General information
    Section
    Medicines used in heart failure
    • Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)
    Indications
    Section
    Antihypertensive medicines
    • Oral > Liquid: 1 mg per mL (as hydrogen maleate)
    • Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)
  202. Enoxaparin General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule
    • Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 120 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule
  203. Entecavir General information
    Section
    Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 0.05 mg per mL
    • Oral > Solid: 0.5 mg; 1 mg
  204. Enzalutamide General information
    Section
    Hormones and antihormones
    Indications
  205. Ephedrine General information
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per mL in 1 mL ampoule (ephedrine hydrochloride)
  206. Epinephrine General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 100 µg per mL in 10 mL ampoule (as acid tartrate or hydrochloride)
    Indications
    Section
    Ophthalmological preparations > Mydriatics
    • Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride)
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Parenteral > General injections > unspecified: 1 mg per mL in ampoule (as hydrochloride or hydrogen tartrate)
    Section
    Antiallergics and medicines used in anaphylaxis
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)
    Indications
  207. Epoetin alfa General information
    Section
    Antianaemia medicines
  208. Epoetin beta General information
    Section
    Antianaemia medicines
  209. Epoetin theta General information
    Section
    Antianaemia medicines
  210. Equine rabies immunoglobulin General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > Locoregional injections > Intradermal: 150 IU per mL in vial; 200 IU per mL in vial; 300 IU per mL in vial; 400 IU per mL in vial
    Indications
  211. Ergocalciferol General information
    Section
    Vitamins and minerals
    • Oral > Liquid: 250 µg per mL (10 000 IU per mL)
    • Oral > Solid: 1.25 mg (50 000 IU)
  212. Ergometrine General information
    Section
    Uterotonics
    • Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)
  213. Erlotinib General information
    Section
    Targeted therapies
    • Oral > Solid: 100 mg; 150 mg
  214. Erythromycin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 0.5%
    Section
    Watch group antibiotics
    Indications
    Second choice
    Therapeutic equivalent to clarithromycin for Acute pharyngitis
  215. Erythropoiesis-stimulating agents General information
    Section
    Antianaemia medicines
    • Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe
  216. Escitalopram General information
    Section
    Medicines for anxiety disorders
    Indications
    Therapeutic equivalent to fluoxetine for Social anxiety disorder Therapeutic equivalent to fluoxetine for Panic disorder Therapeutic equivalent to fluoxetine for Generalised anxiety disorder
    Section
    Medicines for obsessive compulsive disorders
    Indications
    Therapeutic equivalent to fluoxetine for Obsessive-compulsive disorder
    Section
    Medicines for depressive disorders
    Indications
    Therapeutic equivalent to fluoxetine for Depressive disorders
  217. Estradiol cypionate + medroxyprogesterone acetate General information
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 5 mg + 25 mg
  218. Etanercept General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Rheumatoid arthritis Therapeutic equivalent to adalimumab for Crohn disease site
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
  219. Ethambutol General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 100 mg (hydrochloride); 400 mg (hydrochloride); 100 mg tablet (dispersible)
    Indications
  220. Ethambutol + isoniazid + pyrazinamide + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet
    Indications
  221. Ethambutol + isoniazid + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 150 mg tablet
    Indications
  222. Ethanol General information
    Section
    Antiseptics
    • Local > Topical > Solution: 70% (denatured)
  223. Ethinylestradiol + etonogestrel General information
    Section
    Intravaginal contraceptives
    • Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg
  224. Ethinylestradiol + levonorgestrel General information
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 30 µg + 150 µg
  225. Ethinylestradiol + norethisterone General information
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 35 µg + 1 mg
  226. Ethionamide General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 250 mg tablet; 125 mg tablet (dispersible)
  227. Ethosuximide General information
    Section
    Antiseizure medicines
    • Oral > Liquid: 250 mg per 5 mL
    • Oral > Solid: 250 mg
  228. Etonogestrel-releasing implant General information
    Section
    Implantable contraceptives
    • Implant > Subdermal: 68 mg single rod
  229. Etoposide General information
  230. Everolimus General information
    Section
    Targeted therapies
    • Oral > Solid: 2.5 mg; 5 mg; 7.5 mg; 10 mg; 2 mg tablet (dispersible); 3 mg tablet (dispersible); 5 mg tablet (dispersible)
  231. Fentanyl General information
    Section
    Opioid analgesics
    • Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour
  232. Ferrous salt General information
    Section
    Antianaemia medicines
    • Oral > Liquid: 25 mg per mL iron (as sulfate)
    • Oral > Solid: 60 mg iron
  233. Ferrous salt + folic acid General information
    Section
    Antianaemia medicines
    • Oral > Solid > tablet: 60 mg elemental iron + 400 µg tablet; 60 mg elemental iron + 2.8 mg
  234. Fexinidazole General information
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Oral > Solid: 600 mg
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Oral > Solid: 600 mg
  235. Fexofenadine General information
    Section
    Antiallergics and medicines used in anaphylaxis
  236. Filgrastim General information
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
  237. Fluconazole General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 2 mg per mL in vial
    • Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid
    • Oral > Solid > capsule: 50 mg
  238. Flucytosine General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 2.5 g per 250 mL infusion
    • Oral > Solid: 250 mg capsule
    Indications
  239. Fludarabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
    • Oral > Solid: 10 mg tablet (fludarabine phosphate)
  240. Fludrocortisone General information
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid: 100 µg (acetate)
  241. Flunisolide General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide for Asthma
  242. Fluorescein General information
    Section
    Diagnostic agents > Ophthalmic medicines
    • Local > Ophthalmological > Solution (eye drops): 1% (sodium salt)
    Indications
  243. Fluoride General information
    Section
    Dental medicines and preparations
    • Local > Dental > Gel: 2500 to 12500 ppm fluoride (any type)
    • Local > Dental > Toothpaste, cream or gel: 1000 to 1500 ppm fluoride (any type)
    • Local > Dental > Mouthrinse: 230 to 900 ppm fluoride (any type)
    • Local > Dental > Varnish: 22500 ppm fluoride (any type)
    Indications
  244. Fluorouracil General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Ointment: 5%
    Indications
  245. Fluoxetine General information
    Section
    Medicines for depressive disorders
    • Oral > Solid: 20 mg (as hydrochloride)
    Section
    Medicines for anxiety disorders
    • Oral > Solid: 20 mg (as hydrochloride)
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 20 mg (as hydrochloride)
    Indications
    Section
    Medicines for obsessive compulsive disorders
    • Oral > Solid: 20 mg (as hydrochloride)
  246. Fluphenazine General information
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 25 mg per mL in ampoule (decanoate); 25 mg per mL in ampoule (enanthate)
  247. Flutamide General information
    Section
    Hormones and antihormones
    Indications
  248. Fluticasone General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide for Asthma
  249. Fluticasone + formoterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol for Asthma
  250. Fluticasone furoate + vilanterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol for Asthma
  251. Fluvastatin General information
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis
  252. Fluvoxamine General information
    Section
    Medicines for anxiety disorders
    Indications
    Therapeutic equivalent to fluoxetine for Social anxiety disorder Therapeutic equivalent to fluoxetine for Panic disorder Therapeutic equivalent to fluoxetine for Generalised anxiety disorder
    Section
    Medicines for obsessive compulsive disorders
    Indications
    Therapeutic equivalent to fluoxetine for Obsessive-compulsive disorder
    Section
    Medicines for depressive disorders
    Indications
    Therapeutic equivalent to fluoxetine for Depressive disorders
  253. Folic acid General information
    Section
    Antianaemia medicines
    • Oral > Solid: 1 mg tablet; 5 mg tablet
    • Oral > Solid: 400 µg
  254. Fomepizole General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule (sulfate); 1 g per mL in 1.5 mL ampoule (base)
  255. Fosfomycin (injection) General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection
  256. Fresh-frozen plasma General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
  257. Furosemide General information
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
    • Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
    • Oral > Solid > tablet: 40 mg; 20 mg
    Indications
    Section
    Diuretics
    • Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
    • Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
    • Oral > Solid > tablet: 40 mg; 20 mg
  258. Gefitinib General information
    Section
    Targeted therapies
  259. Gemcitabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection
  260. Gentamicin General information
  261. Glass ionomer cement General information
    Section
    Dental medicines and preparations
    • Local > Dental > Powder + liquid: Single-use capsules: 0.4 g powder + 0.09 mL liquid; Multi-use bottle: powder + liquid
    Indications
  262. Glatiramer acetate General information
    Section
    Medicines for multiple sclerosis
    • Parenteral > General injections > SC: 20 mg per mL in pre-filled syringe; 40 mg per mL in pre-filled syringe
  263. Glecaprevir + pibrentasvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 100 mg + 40 mg tablet; 50 mg + 20 mg granules
  264. Gliclazide General information
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release
  265. Glucagon General information
    Section
    Medicines for hypoglycaemia
    • Parenteral > General injections > unspecified: 1 mg per mL
  266. Glucose General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 5% isotonic; 10% hypertonic
    • Parenteral > General injections > IV: 50% hypertonic
  267. Glucose + sodium chloride General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na+ 30 mmol/L and Cl- 30 mmol/L; 5% + 0.9% (equivalent to Na+ 150 mmol/L and Cl- 150 mmol/L); 5% + 0.45% (equivalent to Na+ 75 mmol/L and Cl- 75 mmol/L)
  268. Glutaral General information
    Section
    Disinfectants
    • Local > Topical > Solution: 2%
  269. Glyceryl trinitrate General information
    Section
    Antianginal medicines
    • Oral > Solid: 500 µg sublingual tablet
    Indications
  270. Glycopyrronium General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
  271. Golimumab General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Rheumatoid arthritis Therapeutic equivalent to adalimumab for Crohn disease site
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
  272. Goserelin General information
    Section
    Hormones and antihormones
    Indications
  273. Granisetron General information
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron for Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron for Nausea or vomiting
  274. Griseofulvin General information
    Section
    Antifungal medicines
    • Oral > Liquid: 125 mg per 5 mL
    • Oral > Solid: 125 mg; 250 mg
    Indications
  275. Haemophilus influenzae type b vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  276. Haloperidol General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per mL
    • Oral > Solid: 0.5 mg; 2 mg; 5 mg
    • Parenteral > General injections > unspecified: 5 mg per mL in 1-mL ampoule
    Indications
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 5 mg per mL in ampoule
    • Oral > Solid: 2 mg; 5 mg
  277. Haloperidol decanoate General information
    Section
    Medicines for psychotic disorders
  278. Halothane General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation > liquid:
  279. Heparin sodium General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 1000 IU per mL in 5 mL ampoule; 20000 IU per mL in 5 mL ampoule; 5000 IU per mL in 5 mL ampoule
  280. Hepatitis a vaccine General information
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
  281. Hepatitis b vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  282. Homatropine General information
    Section
    Ophthalmological preparations > Mydriatics
    Indications
    Therapeutic equivalent to atropine for Anterior uveitis
  283. Human papilloma virus (HPV) vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  284. Hydralazine General information
    Section
    Antihypertensive medicines
    • Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)
    • Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)
  285. Hydrochlorothiazide General information
    Section
    Antihypertensive medicines
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 25 mg; 12.5 mg
    Section
    Medicines used in heart failure
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 25 mg
    Indications
    Section
    Diuretics
    • Oral > Solid: 25 mg
    Indications
  286. Hydrocortisone General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid: 5 mg; 10 mg; 20 mg
    Section
    Antiallergics and medicines used in anaphylaxis
    • Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate)
    Indications
    Section
    Anti-inflammatory medicines
    • Local > Rectal > Suppository: 25 mg (acetate)
    • Local > Rectal > Retention enema: 100 mg per 60 mL
    Section
    Dermatological medicines > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Cream: 1% (acetate)
    • Local > Topical > Ointment: 1% (acetate)
  287. Hydromorphone General information
    Section
    Opioid analgesics
    Indications
    Therapeutic equivalent to morphine for Pain
  288. Hydroxocobalamin General information
    Section
    Antianaemia medicines
    • Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)
  289. Hydroxycarbamide (hydroxyurea) General information
    Section
    Cytotoxic medicines
    • Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg
    Section
    Other medicines for haemoglobinopathies
    • Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg
  290. Hydroxychloroquine General information
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 200 mg (as sulfate)
  291. Hyoscine butylbromide General information
    Section
    Medicines for other common symptoms in palliative care
    • Parenteral > General injections > unspecified: 20 mg per mL injection
    Indications
  292. Hyoscine hydrobromide General information
    Section
    Medicines for other common symptoms in palliative care
    • Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch
    • Parenteral > General injections > unspecified: 400 µg per mL injection; 600 µg per mL injection
    Indications
  293. Ibrutinib General information
    Section
    Targeted therapies
    • Oral > Solid: 140 mg
  294. Ibuprofen General information
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 5 mg per mL
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Liquid: 200 mg per 5 mL; 100 mg per 5 mL
    • Oral > Solid > tablet: 200 mg; 400 mg; 600 mg
    Indications
    Section
    Antimigraine medicines > For treatment of acute attack
    • Oral > Liquid: 100 mg per 5 mL; 200 mg per 5 mL
    • Oral > Solid > tablet: 200 mg; 400 mg
    Indications
  295. Imipenem + cilastatin General information
    Section
    Antituberculosis medicines
    Indications
    Section
    Watch group antibiotics
    Indications
    Second choice
    Therapeutic equivalent to meropenem for Neutropenia (high-risk) Therapeutic equivalent to meropenem for Peritoneal abscess (severe) Therapeutic equivalent to meropenem for Peritonitis (severe)
  296. Indapamide General information
    Section
    Antihypertensive medicines
    Indications
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to hydrochlorothiazide for Heart failure
  297. Indometacin General information
    Section
    Medicines administered to the neonate [c]
    Indications
    Therapeutic equivalent to ibuprofen for Patent arterial duct
  298. Infliximab General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Rheumatoid arthritis Therapeutic equivalent to adalimumab for Crohn disease site
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
  299. Influenza vaccine (seasonal) General information
    Section
    Recommendations for immunization programmes with certain characteristics
    • All vaccines should comply with the WHO requirements for biological substances.
  300. Insulin General information
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial (soluble); 100 IU per mL in 10 mL vial (soluble); 100 IU per mL in 3 mL cartridge (soluble); 100 IU per mL in 3 mL pre-filled pen (soluble)
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial (soluble); 100 IU per mL in 10 mL vial (soluble); 100 IU per mL in 3 mL cartridge (soluble); 100 IU per mL in 3 mL pre-filled pen
  301. Insulin degludec General information
    Section
    Insulins
  302. Insulin detemir General information
    Section
    Insulins
  303. Insulin glargine General information
    Section
    Insulins
  304. Intermediate-acting insulin General information
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin
  305. Intraperitoneal dialysis solution General information
    Section
    Peritoneal dialysis solution
    • parenteral solution
  306. Iodine General information
    Section
    Vitamins and minerals
    • Parenteral > General injections > IM: 0.5 mL (240 mg iodine) iodized oil in ampoule; 1 mL (480 mg iodine) iodized oil in ampoule
    • Oral > Liquid: 1 mL (480 mg iodine) iodized oil in ampoule; 0.5 mL (240 mg iodine) iodized oil in ampoule; 0.57 mL (308 mg iodine) iodized oil in dispenser bottle
    • Oral > Solid: 190 mg
    Section
    Antiseptics
    Indications
    Therapeutic equivalent to povidone iodine for Povidone iodine
  307. Iohexol General information
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > unspecified: 140 to 350 mg iodine per mL in 5 mL ampoule; 140 to 350 mg iodine per mL in 10 mL ampoule; 140 to 350 mg iodine per mL in 20 mL ampoule
  308. Ipratropium bromide General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > aerosol: 20 µg per dose
  309. Irinotecan General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial
  310. Isoflurane General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation > liquid:
  311. Isoniazid General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 100 mg tablet; 100 mg tablet (dispersible); 300 mg tablet
    Indications
  312. Isoniazid + pyrazinamide + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 50 mg + 150 mg + 75 mg tablet (dispersible)
    Indications
  313. Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim General information
    Section
    Medicines for prevention of HIV-related opportunistic infections
    • Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)
  314. Isoniazid + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 50 mg + 75 mg tablet (dispersible); 75 mg + 150 mg tablet; 150 mg + 300 mg tablet
    Indications
  315. Isoniazid + rifapentine General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 300 mg + 300 mg tablet (scored)
  316. Isosorbide dinitrate General information
    Section
    Antianginal medicines
    • Oral > Solid: 5 mg sublingual tablet
    Indications
  317. Ivermectin General information
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 3 mg
    Section
    Antifilarials
    • Oral > Solid > tablet: 3 mg
    Section
    Medicines for ectoparasitic infections
    • Oral > Solid > tablet: 3 mg
    Indications
  318. Kanamycin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin for Other specified conjunctivitis Therapeutic equivalent to gentamicin for Infectious blepharitis
  319. Ketamine General information
    Section
    General anaesthetics and oxygen > Injectable medicines
    • Parenteral > General injections > unspecified: 50 mg per mL in 10 mL vial (as hydrochloride)
  320. Lactulose General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 3.1 to 3.7 g per 5 mL oral liquid
    Indications
  321. Lamivudine General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 150 mg tablet
  322. Lamivudine + zidovudine General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet
  323. Lamotrigine General information
    Section
    Antiseizure medicines
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)
  324. Latanoprost General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 50 µg per mL eye drops
  325. Ledipasvir + sofosbuvir General information
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 90 mg + 400 mg tablet
  326. Lenalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 25 mg
  327. Letrozole General information
    Section
    Ovulation inducers
    • Oral > Solid > dosage form: 2.5 mg
  328. Leuprorelin General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe
  329. Levamisole General information
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 50 mg (as hydrochloride); 150 mg (as hydrochloride)
    Indications
  330. Levetiracetam General information
    Section
    Antiseizure medicines
    • Oral > Liquid: 100 mg per mL
    • Oral > Solid > tablet: 250 mg; 500 mg; 750 mg; 1000 mg
    • Parenteral > General injections > IV: 500 mg per 5 mL in 5 mL vial; 5 mg per mL in 100 mL bag; 10 mg per mL in 100 mL bag; 15 mg per mL in 100 mL bag
  331. Levodopa + benserazide General information
    Section
    Medicines for parkinsonism
    Indications
    Therapeutic equivalent to levodopa + carbidopa for Parkinson disease
  332. Levodopa + carbidopa General information
    Section
    Medicines for parkinsonism
    • Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet
  333. Levofloxacin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 250 mg tablet; 500 mg tablet; 750 mg tablet; 100 mg tablet (dispersible)
  334. Levonorgestrel General information
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 750 µg [2]; 1.5 mg [1]
    • Oral > Solid: 30 µg
    Section
    Intrauterine devices
    • Intrauterine system with reservoir containing 52 mg of levonorgestrel.
  335. Levonorgestrel-releasing implant General information
    Section
    Implantable contraceptives
    • Implant > Subdermal: 75 mg per rod (two-rods)
  336. Levothyroxine General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)
    Indications
  337. Lidocaine General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule (hydrochloride)
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution
    • Parenteral > Locoregional injections > Other: 1% in vial (hydrochloride); 2% in vial (hydrochloride)
    • Local > Topical > unspecified: 2 to 4% (hydrochloride)
  338. Lidocaine + epinephrine General information
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial
    • Local > Dental > Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine
  339. Linezolid General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 600 mg tablet; 150 mg tablet (dispersible)
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid > dispersible tablet: 150 mg
    • Oral > Solid > tablet: 600 mg
  340. Lisinopril + amlodipine General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg
  341. Lisinopril + hydrochlorothiazide General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg
  342. Lithium carbonate General information
    Section
    Medicines for bipolar disorders
    • Oral > Solid: 300 mg
  343. Long-acting insulin analogues General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
  344. Loperamide General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 2 mg solid oral dosage form
    Indications
  345. Lopinavir + ritonavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable); 40 mg + 10 mg
  346. Loratadine General information
    Section
    Antiallergics and medicines used in anaphylaxis
    • Oral > Liquid: 1 mg per mL
    • Oral > Solid: 10 mg
  347. Lorazepam General information
    Section
    Antiseizure medicines
    • Parenteral > General injections > IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule
    Section
    Medicines for anxiety disorders
    Indications
    Therapeutic equivalent to diazepam for Anxiety
  348. Losartan General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
    Section
    Medicines used in heart failure
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
    Indications
  349. Lovastatin General information
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis
  350. Lugol's solution General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Liquid: 13% w/v (about 130 mg/mL total iodine)
    Indications
  351. Magnesium sulfate General information
    Section
    Antiseizure medicines
    • Parenteral > General injections > IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)
    • Parenteral > General injections > IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)
  352. Mannitol General information
    Section
    Diuretics
    • Parenteral > General injections > IV: 10% solution; 20% solution
  353. Measles vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  354. Mebendazole General information
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)
    Section
    Cysticidal medicines
    • Oral > Solid > tablet: 500 mg (chewable); 100 mg (chewable)
  355. Medroxyprogesterone acetate General information
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 150 mg per mL in 1 mL vial
    • Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system
    Section
    Progestogens
    • Oral > Solid: 5 mg
  356. Mefloquine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 250 mg tablet (hydrochloride)
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 250 mg tablet (hydrochloride)
  357. Meglumine antimoniate General information
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule
  358. Meglumine iotroxate General information
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL
  359. Melarsoprol General information
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)
  360. Melphalan General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection
    • Oral > Solid: 2 mg
  361. Meningococcal meningitis vaccine General information
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
  362. Mercaptopurine General information
    Section
    Cytotoxic medicines
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 50 mg tablet
  363. Meropenem General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
  364. Meropenem + vaborbactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection
  365. Mesalazine General information
    Section
    Anti-inflammatory medicines
    Indications
    Therapeutic equivalent to sulfasalazine for Crohn disease site Therapeutic equivalent to sulfasalazine for Ulcerative colitis
  366. Metformin General information
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 500 mg (hydrochloride)
  367. Methadone General information
    Section
    Medicines for disorders due to psychoactive substance use
    • Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
    Section
    Opioid analgesics
    • Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
    • Oral > Solid: 5 mg (methadone hydrochloride); 10 mg (methadone hydrochloride)
  368. Methimazole General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 5 mg; 10 mg; 20 mg
    Indications
  369. Methotrexate General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid > tablet: 2.5 mg (as sodium salt)
    Section
    Medicines for juvenile joint diseases
    • Oral > Solid > tablet: 2.5 mg (as sodium salt)
  370. Methoxy polyethylene glycol-epoetin beta General information
    Section
    Antianaemia medicines
  371. Methyldopa General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 250 mg
  372. Methylergometrine General information
    Section
    Uterotonics
    Indications
    Therapeutic equivalent to ergometrine for Postpartum haemorrhage
  373. Methylprednisolone General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)
  374. Methylthioninium chloride General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 10 mg per mL in 10 mL ampoule
  375. Metoclopramide General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 5 mg per 5 mL
    • Oral > Solid: 10 mg (hydrochloride)
    • Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
    Indications
    Section
    Antiemetic medicines
    • Oral > Liquid: 5 mg per 5 mL
    • Oral > Solid: 10 mg (hydrochloride)
    • Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
  376. Metoprolol General information
    Section
    Antianginal medicines
    Indications
    Therapeutic equivalent to bisoprolol for Angina pectoris
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to bisoprolol for Heart failure
    Section
    Antiarrhythmic medicines
    Indications
    Therapeutic equivalent to bisoprolol for Cardiac arrhythmia
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to bisoprolol for Essential hypertension
  377. Metronidazole General information
    Section
    Antiamoebic and antigiardiasis medicines
    • Oral > Liquid: 200 mg per 5 mL (as benzoate)
    • Parenteral > General injections > unspecified: 500 mg in 100 mL vial
    • Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
    Indications
    Section
    Access group antibiotics
    • Oral > Liquid: 200 mg per 5 mL (as benzoate)
    • Local > Rectal > Suppository: 500 mg suppository; 1 g suppository
    • Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
    • Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
    • Local > Rectal > Suppository: 1 g suppository; 500 mg suppository
    • Oral > Solid: 200 to 500 mg tablet
  378. Micafungin General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection
  379. Miconazole General information
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Cream: 2% (nitrate)
    • Local > Topical > Ointment: 2% (nitrate)
  380. Midazolam General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per mL oral liquid
    • Oral > Solid: 7.5 mg solid oral dosage form; 15 mg solid oral dosage form
    • Parenteral > General injections > unspecified: 1 mg per mL injection; 5 mg per mL injection
    Indications
    Section
    Antiseizure medicines
    • Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial (for buccal administration); 5 mg per mL in 1 mL vial (for buccal administration); 5 mg per mL in 3 mL vial (for buccal administration)
    • Local > Buccal > Solution: 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe; 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)
    Indications
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > IV: 1 mg per mL
    • Oral > Liquid: 2 mg per mL
    • Oral > Solid: 15 mg tablet; 7.5 mg tablet
  381. Mifepristone - misoprostol General information
    Section
    Uterotonics
    • Oral > Solid: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package
  382. Miltefosine General information
    Section
    Antileishmaniasis medicines
    • Oral > Solid: 10 mg; 50 mg
  383. Misoprostol General information
    Section
    Uterotonics
    • Oral > Solid: 200 µg
    • Local > Vaginal > tablet: 25 µg
  384. Mometasone General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide for Asthma
  385. Mometasone + formoterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol for Asthma
  386. Morphine General information
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > IV: 10 mg in 1 mL ampoule (sulfate OR hydrochloride)
    Section
    Opioid analgesics
    • Oral > Liquid: 10 mg per 5 mL (morphine hydrochloride or morphine sulfate)
    • Oral > Solid: 10 mg immediate release (morphine sulfate); 10 to 200 mg slow release (morphine hydrochloride or morphine sulfate)
    • Oral > Other: 20 to 200 mg slow release granules to mix with water (morphine sulfate)
    • Parenteral > General injections > unspecified: 10 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate)
    Indications
  387. Moxifloxacin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 400 mg tablet; 100 mg tablet (dispersible)
    • Oral > Solid: 400 mg tablet
  388. Multiple micronutrient powder General information
    Section
    Vitamins and minerals
    • Oral > Other:
  389. Multiple micronutrient supplement General information
    Section
    Other medicines administered to the mother
    • Tablet containing:
    • Vit A: 800 mcg retinol activity equivalent
    • Vit C: 70 mg
    • Vit D: 5 mcg (200 IU)
    • Vit E: 10 mg alpha tocopherol equivalent
    • Vit B1: 1.4 mg
    • Vit B2: 1.4 mg
    • Vit B3: 18 mg niacin equivalent
    • Vit B6: 1.9 mg
    • Folic acid: 400 mcg
    • Vit B12: 2.6 mcg
    • Iron: 30 mg
    • Iodine: 150 mcg
    • Zinc: 15 mg
    • Selenium: 65 mcg
    • Copper: 2 mg
  390. Mumps vaccine General information
    Section
    Recommendations for immunization programmes with certain characteristics
    • All vaccines should comply with the WHO requirements for biological substances.
  391. Mupirocin General information
    Section
    Dermatological medicines > Anti-infective medicines
    • Local > Topical > Cream: 2% (as mupirocin calcium)
    • Local > Topical > Ointment: 2%
  392. Nadroparin General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin for Acute ischaemic heart disease Therapeutic equivalent to enoxaparin for Venous thromboembolism
  393. Naloxone General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule (naloxone hydrochloride)
  394. Naltrexone General information
    Section
    Medicines for alcohol use disorders
    • Parenteral > General injections > IM: 380 mg in vial (extended-release)
    • Oral > Solid > tablet: 50 mg
  395. Natamycin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Suspension: 5% eye drops
  396. Neostigmine General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Oral > Solid: 15 mg (neostigmine bromide)
    • Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
  397. Netilmicin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin for Other specified conjunctivitis Therapeutic equivalent to gentamicin for Infectious blepharitis
  398. Nevirapine General information
    Section
    Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
    • Oral > Liquid: 50 mg per 5 mL oral solution
    • Oral > Solid: 200 mg tablet; 50 mg tablet (dispersible)
  399. Niclosamide General information
    Section
    Intestinal anthelminthics
    • Oral > Solid: 500 mg tablet (chewable)
  400. Nicotinamide General information
    Section
    Vitamins and minerals
    • Oral > Solid: 50 mg
    Indications
  401. Nicotine replacement therapy General information
    Section
    Medicines for disorders due to psychoactive substance use
    • Oral > Other: 2 mg chewing gum; 4 mg chewing gum; 2 mg lozenge; 4 mg lozenge; 1 mg per actuation oral spray
    • Local > Topical > Transdermal patch: 5 to 30 mg per 16 hour; 7 to 21 mg per 24 hour
  402. Nifedipine General information
    Section
    Antioxytocics (tocolytics)
    • Oral > Solid: 10 mg (immediate-release)
  403. Nifurtimox General information
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Oral > Solid > tablet: 120 mg (scored); 30 mg (scored)
    Section
    American trypanosomiasis
    • Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)
    Indications
  404. Nilotinib General information
    Section
    Targeted therapies
    • Oral > Solid: 150 mg capsule; 200 mg capsule
  405. Nilutamide General information
    Section
    Hormones and antihormones
    Indications
  406. Nitrofurantoin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 25 mg per 5 mL oral liquid
    • Oral > Solid > dosage form: 100 mg; 50 mg
    Indications
  407. Nitrous oxide General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation:
  408. Nivolumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
    Indications
  409. Norethisterone General information
    Section
    Progestogens
  410. Norethisterone enantate General information
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution
  411. Normal immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IV: 5% protein solution; 10% protein solution
    • Parenteral > General injections > IM: 16% protein solution
    • Parenteral > General injections > SC: 15% protein solution; 16% protein solution
  412. Nystatin General information
    Section
    Antifungal medicines
    • Oral > Liquid: 100000 IU per mL
    • Local > Topical > Other: 100000 IU pessary
    • Oral > Solid > dosage form: 500000 IU
    • Oral > Solid > lozenge: 100000 IU
    Indications
  413. Octreotide General information
    Section
    Medicines for disorders of the pituitary hormone system
    • Parenteral > General injections > IM: 20 mg in vial (modified-release, as acetate) plus diluent
    • Parenteral > General injections > SC: 0.05 mg per mL in 1 mL vial (immediate-release, as acetate); 0.1 mg per mL in 1 mL vial (immediate-release, as acetate); 0.5 mg per mL in 1 mL vial (immediate-release, as acetate)
  414. Ofloxacin General information
    Section
    Ear, nose and throat medicines [c]
    Indications
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 0.3%
  415. Olanzapine General information
    Section
    Medicines for bipolar disorders
    Indications
    Therapeutic equivalent to quetiapine for Bipolar or related disorders
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 10 mg in vial powder for injection
  416. Omeprazole General information
    Section
    Antiulcer medicines
    • Oral > Liquid: 20 mg powder for oral liquid; 40 mg powder for oral liquid
    • Oral > Solid: 10 mg; 20 mg; 40 mg
    • Parenteral > General injections > IV: 40 mg in vial
  417. Ondansetron General information
    Section
    Medicines for other common symptoms in palliative care
    • Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)
    • Oral > Liquid: 4 mg per 5 mL (ondansetron base)
    • Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base)
    Indications
    Section
    Antiemetic medicines
    • Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)
    • Oral > Liquid: 4 mg per 5 mL (ondansetron base)
    • Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base); 24 mg (ondansetron base)
  418. Oral rehydration salts General information
    Section
    Oral rehydration
    • Powder for dilution in 200 mL, 500 mL, 1 L:
    • - glucose 75 mEq
    • - sodium 75 mEq or mmol/L
    • - chloride 65 mEq or mmol/L
    • - potassium 20 mEq or mmol/L
    • - citrate 10 mmol/L
    • - osmolarity 245 mOsm/L
    • - glucose 13.5 g/L
    • - sodium chloride 2.6 g/L
    • - potassium chloride 1.5 g/L
    • - trisodium citrate dihydrate 2.9 g/L
    Indications
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Oral
    • Powder for dilution in 200 mL, 500 mL, 1 L:
    • - glucose 75 mEq
    • - sodium 75 mEq or mmol/L
    • - chloride 65 mEq or mmol/L
    • - potassium 20 mEq or mmol/L
    • - citrate 10 mmol/L
    • - osmolarity 245 mOsm/L
    • - glucose 13.5 g/L
    • - sodium chloride 2.6 g/L
    • - potassium chloride 1.5 g/L
    • - trisodium citrate dihydrate 2.9 g/L
  419. Oral rehydration salts - zinc sulfate General information
    Section
    Medicines used in diarrhoea
    • Oral > Other: ORS powder for dilution and zinc sulfate solid oral dosage form 20 mg (co-packaged)
    Indications
  420. Oseltamivir General information
    Section
    Other antivirals
    • Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)
  421. Oxaliplatin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial
  422. Oxamniquine General information
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Liquid: 250 mg per 5 mL
    • Oral > Solid: 250 mg capsule
  423. Oxycodone General information
    Section
    Opioid analgesics
    Indications
    Therapeutic equivalent to morphine for Pain
  424. Oxygen General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation: (medical gas)
    Section
    Medical gases
    • Respiratory > Inhalation:
  425. Oxytetracycline General information
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to tetracycline for Other specified conjunctivitis Therapeutic equivalent to tetracycline for Infectious keratitis Therapeutic equivalent to tetracycline for Trachoma Therapeutic equivalent to tetracycline for Infectious blepharitis
  426. Oxytocin General information
    Section
    Uterotonics
    • Parenteral > General injections > unspecified: 10 IU per mL
  427. P-aminosalicylate sodium General information
    Section
    Antituberculosis medicines
    • Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid)
  428. Paliperidone General information
    Section
    Medicines for bipolar disorders
    Indications
    Therapeutic equivalent to quetiapine for Bipolar or related disorders
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM: 25 mg in pre-filled syringe (as palmitate); 50 mg in pre-filled syringe (as palmitate); 75 mg in pre-filled syringe (as palmitate); 100 mg in pre-filled syringe (as palmitate); 150 mg in pre-filled syringe (as palmitate)
  429. Palonosetron General information
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron for Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron for Nausea or vomiting
  430. Pancreatic enzymes General information
    Section
    Pancreatic enzymes
    • Oral > Solid: Age-appropriate formulations and doses including lipase, protease and amylase.
  431. Paracetamol (acetaminophen) General information
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL
    • Local > Rectal > Suppository: 100 mg; 250 mg
    • Oral > Solid > dispersible tablet: 100 mg; 250 mg
    • Oral > Solid > tablet: 250 mg; 325 mg; 500 mg
    Indications
    Section
    Antimigraine medicines > For treatment of acute attack
    • Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL
    • Local > Rectal > Suppository: 250 mg
    • Oral > Solid > dispersible tablet: 100 mg; 250 mg
    • Oral > Solid > tablet: 250 mg; 325 mg; 500 mg
    Indications
  432. Paromomycin General information
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)
  433. Paroxetine General information
    Section
    Medicines for anxiety disorders
    Indications
    Therapeutic equivalent to fluoxetine for Social anxiety disorder Therapeutic equivalent to fluoxetine for Panic disorder Therapeutic equivalent to fluoxetine for Generalised anxiety disorder
    Section
    Medicines for obsessive compulsive disorders
    Indications
    Therapeutic equivalent to fluoxetine for Obsessive-compulsive disorder
    Section
    Medicines for depressive disorders
    Indications
    Therapeutic equivalent to fluoxetine for Depressive disorders
  434. Pegaspargase General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection
  435. Pegfilgrastim General information
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe
  436. Pembrolizumab General information
    Section
    Immunomodulators
    Indications
    Therapeutic equivalent to nivolumab for Melanoma of skin
  437. Penicillamine General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: 250 mg
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 250 mg
  438. Pentamidine General information
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Oral > Solid: 200 mg tablet; 300 mg tablet
    Indications
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection
  439. Permethrin General information
    Section
    Dermatological medicines > Scabicides and pediculicides
    • Local > Topical > Cream: 5%
    • Local > Topical > Lotion: 1%
  440. Pertussis vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  441. Phenobarbital General information
    Section
    Antiseizure medicines
    • Oral > Liquid: 15 mg per 5 mL
    • Oral > Solid: 15 to 100 mg
    • Parenteral > General injections > IV: 200 mg per mL (phenobarbital sodium); 30 mg per mL (phenobarbital sodium); 60 mg per mL (phenobarbital sodium)
  442. Phenoxymethylpenicillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
    • Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)
  443. Phenytoin General information
    Section
    Antiseizure medicines
    • Oral > Liquid: 30 mg per 5 mL (phenytoin)
    • Parenteral > General injections > unspecified: 50 mg per mL in vial (phenytoin sodium)
    • Oral > Solid > tablet: 50 mg (phenytoin) (chewable)
    • Oral > Solid > dosage form: 50 mg (phenytoin sodium); 25 mg (phenytoin sodium); 100 mg (phenytoin sodium)
  444. Phytomenadione General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule
    • Oral > Solid: 10 mg tablet
  445. Pilocarpine General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)
  446. Piperacillin + tazobactam General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection
  447. Platelets General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
  448. Plazomicin General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 500 mg per 10 mL (Injection)
  449. Pneumococcal vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  450. Podophyllotoxin General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
    Therapeutic equivalent to podophyllum resin for Plantar warts Therapeutic equivalent to podophyllum resin for Anogenital warts
  451. Podophyllum resin General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Solution: 10 to 25%
  452. Poliomyelitis vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  453. Polygeline General information
    Section
    Plasma substitutes
    • Parenteral > General injections > IV: 3.5% injectable solution
    Indications
    Therapeutic equivalent to dextran 70 for Hypovolaemia
  454. Polymyxin B (injection) General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > unspecified: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)
  455. Potassium chloride General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K+ 1.5 mmol/mL and Cl- 1.5 mmol/mL); 7.5% solution for dilution (equivalent to K+ 1 mmol/mL and Cl- 2 mmol/mL); 15% solution for dilution (equivalent to K+ 2 mmol/mL and Cl- 2 mmol/mL)
    Indications
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Oral
    • Oral > Liquid: powder for solution
    Indications
  456. Potassium ferric hexacyanoferrate General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: Powder for oral administration
  457. Potassium iodide General information
    Section
    Antifungal medicines
    • Local > Topical > Solution: Saturated solution
    Indications
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 60 mg
    Indications
  458. Potassium permanganate General information
    Section
    Dermatological medicines > Anti-infective medicines
    • Local > Topical > Solution: aqueous solution: 1:10 000
  459. Povidone iodine General information
    Section
    Antiseptics
    • Local > Topical > Solution: 10% (equivalent to 1% available iodine)
    Indications
  460. Pravastatin General information
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis
  461. Praziquantel General information
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg
    Section
    Cysticidal medicines
    • Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg
  462. Precipitated sulfur General information
    Section
    Dermatological medicines > Scabicides and pediculicides
    • Local > Topical > Ointment:
    Indications
    Therapeutic equivalent to benzyl benzoate for Pthiriasis Therapeutic equivalent to benzyl benzoate for Pediculosis corporis Therapeutic equivalent to benzyl benzoate for Pediculosis capitis Therapeutic equivalent to benzyl benzoate for Scabies
  463. Prednisolone General information
    Section
    Anti-inflammatory medicines
    • Local > Rectal > Retention enema:
    • Local > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)
    Section
    Antiallergics and medicines used in anaphylaxis
    • Oral > Liquid: 5 mg per mL
    • Oral > Solid: 5 mg; 25 mg
    Section
    Ophthalmological preparations > Anti-inflammatory agents
    • Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)
  464. Prednisone General information
    Section
    Antiallergics and medicines used in anaphylaxis
  465. Pretomanid General information
    Section
    Antituberculosis medicines
    • Oral > Solid > tablet: 200 mg
  466. Primaquine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 7.5 mg tablet (as phosphate); 15 mg tablet (as phosphate)
  467. Procaine benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection
    Indications
  468. Procarbazine General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 50 mg (as hydrochloride)
    Indications
  469. Progesterone vaginal ring General information
    Section
    Intravaginal contraceptives
    • Local > Vaginal > vaginal ring: 2.074 g micronized progesterone
  470. Proguanil General information
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 100 mg tablet (hydrochloride)
  471. Propanol General information
    Section
    Antiseptics
    Indications
    Therapeutic equivalent to ethanol for Denatured alcohol
  472. Propofol General information
    Section
    General anaesthetics and oxygen > Injectable medicines
    • Parenteral > General injections > IV: 10 mg per mL; 20 mg per mL
  473. Propranolol General information
    Section
    Antimigraine medicines > For prophylaxis
    • Oral > Solid: 40 mg tablet (hydrochloride); 20 mg tablet (hydrochloride)
    Indications
  474. Propylthiouracil General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 50 mg
    Indications
  475. Prostaglandin E1 General information
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 0.5 mg per mL in alcohol
  476. Prostaglandin E2 General information
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 1 mg per mL
  477. Protamine sulfate General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule
  478. Protionamide General information
    Section
    Antituberculosis medicines
  479. Pyrantel General information
    Section
    Intestinal anthelminthics
    • Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)
  480. Pyrazinamide General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 400 mg; 150 mg tablet (dispersible); 500 mg
    Indications
  481. Pyridostigmine General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 1 mg in 1 mL ampoule (pyridostigmine bromide)
    • Oral > Solid: 60 mg (pyridostigmine bromide)
  482. Pyridoxine General information
    Section
    Vitamins and minerals
    • Oral > Solid: 25 mg (hydrochloride)
  483. Pyrimethamine General information
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Oral > Solid: 25 mg
    Indications
  484. Quetiapine General information
    Section
    Medicines for psychotic disorders
    Section
    Medicines for bipolar disorders
    • Oral > Solid > tablet: 25 mg (immediate-release); 100 mg (immediate-release); 150 mg (immediate-release); 200 mg (immediate-release); 300 mg (immediate-release); 50 mg (modified-release); 150 mg (modified-release); 200 mg (modified-release); 300 mg (modified-release); 400 mg (modified-release)
  485. Quinine General information
    Section
    Antimalarial medicines > For curative treatment
    • Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (quinine hydrochloride)
    • Oral > Solid: 300 mg (quinine sulfate or quinine bisulfate)
  486. Rabies vaccine General information
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
  487. Raltegravir General information
    Section
    Antiretrovirals > Integrase inhibitors
    • Oral > Liquid: 100 mg granules for oral suspension
    • Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)
  488. Ranitidine General information
    Section
    Antiulcer medicines
    • Oral > Liquid: 75 mg per 5 mL (as hydrochloride)
    • Oral > Solid: 150 mg (as hydrochloride)
    • Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)
  489. Rasburicase General information
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 1.5 mg in vial powder and solvent for solution; 7.5 mg in vial powder and solvent for solution
  490. Ravidasvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid > tablet: 200 mg
  491. Ready to use therapeutic food General information
    Section
    Therapeutic foods
    • Biscuit or paste of nutritional composition as determined by the UN joint statement on the community-based management of severe acute malnutrition and Codex alimentarius guidelines.
  492. Realgar-indigo naturalis formulation General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)
  493. Red blood cells General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
  494. Resin-based composite (high-viscosity) General information
    Section
    Dental medicines and preparations
    • Local > Topical > Other: Single-use capsule or multi-use syringe
    Indications
  495. Resin-based composite (low-viscosity) General information
    Section
    Dental medicines and preparations
    • Local > Topical > Other: Single-use applicator or multi-use bottle
    Indications
  496. Retinol General information
    Section
    Vitamins and minerals
    • Parenteral > General injections > IM: 100000 IU in 2 mL ampoule (as palmitate) water-miscible injection
    • Oral > Liquid: 100000 IU per mL (as palmitate) oral oily solution in multidose dispenser
    • Oral > Solid: 10000 IU (as palmitate) sugar-coated tablet; 200000 IU (as palmitate) capsule; 50000 IU (as palmitate) capsule; 100000 IU (as palmitate) capsule
  497. Ribavirin General information
    Section
    Other antivirals
    • Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
    • Oral > Solid: 200 mg; 400 mg; 600 mg
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
    • Oral > Solid: 200 mg; 400 mg; 600 mg
  498. Riboflavin General information
    Section
    Vitamins and minerals
    • Oral > Solid: 5 mg
  499. Rifabutin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 150 mg
    Indications
  500. Rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 150 mg; 300 mg
    Indications
    Section
    Antileprosy medicines
    • Oral > Liquid: 20 mg per mL
    • Oral > Solid: 150 mg; 300 mg
    Indications
  501. Rifapentine General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 150 mg tablet; 300 mg tablet
  502. Risperidone General information
    Section
    Medicines for psychotic disorders
    • Parenteral > General injections > IM:
    • Oral > Solid: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg; 6 mg
  503. Ritonavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)
  504. Rituximab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
    Section
    Medicines for multiple sclerosis
    • Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial
  505. Rivaroxaban General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation
  506. Rotavirus vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  507. Rubella vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  508. Salbutamol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Parenteral > General injections > IV: 50 µg per mL in 5 mL ampoule (as sulfate)
    • Respiratory > Inhalation > aerosol: 100 µg per dose (as sulfate); 100 µg per dose (as sulfate) metered-dose inhaler
    • Respiratory > Inhalation > solution: 5 mg per mL (as sulfate) for use in nebulizers
  509. Salicylic acid General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Solution: 5%
  510. Selenium sulfide General information
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Suspension: 2% detergent-based
  511. Senna General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 7.5 mg per 5 mL oral liquid
    Indications
    Section
    Laxatives
    • Oral > Solid: 7.5 mg (sennosides) (or traditional dosage forms)
    Indications
  512. Sertraline General information
    Section
    Medicines for anxiety disorders
    Indications
    Therapeutic equivalent to fluoxetine for Social anxiety disorder Therapeutic equivalent to fluoxetine for Panic disorder Therapeutic equivalent to fluoxetine for Generalised anxiety disorder
    Section
    Medicines for obsessive compulsive disorders
    Indications
    Therapeutic equivalent to fluoxetine for Obsessive-compulsive disorder
    Section
    Medicines for depressive disorders
    Indications
    Therapeutic equivalent to fluoxetine for Depressive disorders
  513. Sevoflurane General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation > liquid:
  514. Silver diamine fluoride General information
    Section
    Dental medicines and preparations
    • Local > Dental > Solution: 38% w/v
    Indications
  515. Silver sulfadiazine General information
    Section
    Dermatological medicines > Anti-infective medicines
    • Local > Topical > Cream: 1%
    Indications
  516. Simvastatin General information
    Section
    Lipid-lowering agents
    • Oral > Solid: 5 mg; 10 mg; 20 mg; 40 mg
  517. Sodium calcium edetate General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 200 mg per mL in 5 mL ampoule
  518. Sodium chloride General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na+ 154 mmol/L and Cl- 154 mmol/L)
  519. Sodium hydrogen carbonate General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 1.4% isotonic (equivalent to Na+ 167 mmol/L and HCO3- 167 mmol/L); 8.4% in 10 mL ampoule (equivalent to Na+ 1000 mmol/L and HCO3- 1000 mmol/L)
    Indications
  520. Sodium nitrite General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 30 mg per mL in 10 mL ampoule
  521. Sodium nitroprusside General information
    Section
    Antihypertensive medicines
    • Parenteral > General injections > IV: 50 mg in ampoule powder for infusion
  522. Sodium stibogluconate General information
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial
  523. Sodium thiosulfate General information
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Solution: 15%
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 250 mg per mL in 50 mL ampoule
  524. Sofosbuvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 400 mg; 200 mg
  525. Sofosbuvir + velpatasvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 400 mg + 100 mg tablet; 200 mg + 50 mg tablet
  526. Spectinomycin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection
    Indications
  527. Spironolactone General information
    Section
    Medicines used in heart failure
    • Oral > Solid: 25 mg
    Indications
    Section
    Diuretics
    • Oral > Liquid: 10 mg per 5 mL; 25 mg per 5 mL; 5 mg per 5 mL
    • Oral > Solid: 25 mg
  528. Streptokinase General information
    Section
    Thrombolytic medicines
    • Parenteral > General injections > IV: 1.5 million IU in vial powder for injection
  529. Streptomycin (injection) General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial
  530. Succimer General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: 100 mg
  531. Sulfadiazine General information
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Oral > Solid: 500 mg
    Indications
  532. Sulfadoxine + pyrimethamine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 500 mg + 25 mg tablet
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 500 mg + 25 mg tablet
    • Oral > Solid: 250 mg + 12.5 mg tablet
  533. Sulfamethoxazole + trimethoprim General information
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule
    • Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
    • Oral > Solid > dispersible tablet: 100 mg + 20 mg
    Indications
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule
    • Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
    • Oral > Solid > dispersible tablet: 100 mg + 20 mg
  534. Sulfasalazine General information
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 500 mg
    Section
    Anti-inflammatory medicines
    • Oral > Solid: 500 mg
    • Local > Rectal > Suppository: 500 mg
    • Local > Rectal > Retention enema:
  535. Sumatriptan General information
    Section
    Antimigraine medicines > For treatment of acute attack
    • Oral > Solid: 50 mg
    Indications
  536. Suramin sodium General information
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Parenteral > General injections > IV: 1 g in vial
  537. Surfactant General information
    Section
    Medicines administered to the neonate [c]
    • Respiratory > Suspension: 80 mg per mL for intratracheal instillation; 25 mg per mL for intratracheal instillation
  538. Suxamethonium General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 50 mg per mL in 2 mL ampoule (suxamethonium chloride); powder for injection (suxamethonium chloride) in vial
    Indications
  539. Tacalcitol General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    Indications
  540. Tacrolimus General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 5 mg per mL in 1 mL vial
    • Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension
    • Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)
  541. Tamoxifen General information
    Section
    Hormones and antihormones
    • Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)
  542. Tedizolid General information
    Section
    Reserve group antibiotics
  543. Telmisartan + amlodipine General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg
  544. Telmisartan + hydrochlorothiazide General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg
  545. Tenofovir disoproxil fumarate General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)
    Section
    Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)
  546. Terbinafine General information
    Section
    Dermatological medicines > Antifungal medicines
    • Local > Topical > Cream: 1% terbinafine hydrochloride
    • Local > Topical > Ointment: 1% terbinafine hydrochloride
  547. Terbutaline General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to salbutamol for Chronic obstructive pulmonary disease Therapeutic equivalent to salbutamol for Asthma
  548. Terizidone General information
    Section
    Antituberculosis medicines
  549. Testosterone General information
    Section
    Androgens
    • Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate)
  550. Tetanus vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  551. Tetracaine General information
    Section
    Ophthalmological preparations > Local anaesthetics
    • Local > Ophthalmological > Solution (eye drops): 0.5% (hydrochloride)
  552. Tetracycline General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)
  553. Thalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 50 mg
  554. Thiamine General information
    Section
    Vitamins and minerals
    • Oral > Solid: 50 mg (hydrochloride)
  555. Thiopental General information
    Section
    General anaesthetics and oxygen > Injectable medicines
    Indications
  556. Tick-borne encephalitis vaccine General information
    Section
    Recommendations for certain regions
    • All vaccines should comply with the WHO requirements for biological substances.
  557. Timolol General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate)
  558. Tinidazole General information
    Section
    Antiamoebic and antigiardiasis medicines
    Indications
    Therapeutic equivalent to metronidazole for Amoebiasis
  559. Tioguanine General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 40 mg
  560. Tiotropium bromide General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > dry powder: 18 µg capsule
    • Respiratory > Inhalation > solution: 1.25 µg per actuation; 2.5 µg per actuation
  561. Tobramycin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin for Other specified conjunctivitis Therapeutic equivalent to gentamicin for Infectious blepharitis
  562. Torasemide General information
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to furosemide for Heart failure
    Section
    Diuretics
    Indications
    Therapeutic equivalent to furosemide for Anuria or oliguria Therapeutic equivalent to furosemide for Oedema
  563. Tranexamic acid General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Section
    Other medicines administered to the mother
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
  564. Trastuzumab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection
  565. Triamcinolone acetonide General information
    Section
    Medicines for juvenile joint diseases
    Indications
  566. Triamcinolone hexacetonide General information
    Section
    Medicines for juvenile joint diseases
    • Parenteral > Locoregional injections > Intra-articular: 20 mg per mL in vial
  567. Triclabendazole General information
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Solid > tablet: 250 mg (scored)
  568. Trihexyphenidyl General information
    Section
    Medicines for parkinsonism
    Indications
    Therapeutic equivalent to biperiden for Parkinson disease
  569. Trimethoprim General information
    Section
    Access group antibiotics
    • Oral > Liquid: 50 mg per mL
    • Oral > Solid: 100 mg; 200 mg
    Indications
  570. Triptorelin General information
    Section
    Hormones and antihormones
    Indications
  571. Tropicamide General information
    Section
    Diagnostic agents > Ophthalmic medicines
    • Local > Ophthalmological > Solution (eye drops): 0.5%
    Indications
  572. Tropisetron General information
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron for Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron for Nausea or vomiting
  573. Tuberculin, purified protein derivative General information
    Section
    Immunologicals > Diagnostic agents
    • Parenteral > Locoregional injections > Intradermal:
  574. Typhoid vaccine General information
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
  575. Ulipristal General information
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 30 mg tablet (ulipristal acetate)
  576. Umeclidinium General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
  577. Urea General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Cream: 10%; 5%
    • Local > Topical > Ointment: 10%; 5%
  578. Valaciclovir General information
    Section
    Antiherpes medicines
    Indications
    Therapeutic equivalent to aciclovir for Zoster Therapeutic equivalent to aciclovir for Varicella Therapeutic equivalent to aciclovir for Herpes simplex infections
  579. Valganciclovir General information
    Section
    Other antivirals
    • Oral > Liquid: 50 mg per mL powder for oral solution
    • Oral > Solid: 450 mg Tablet
  580. Valproic acid (sodium valproate) General information
    Section
    Antiseizure medicines
    • Oral > Liquid: 200 mg per 5 mL
    • Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable)
    • Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 3 mL ampoule
    Section
    Medicines for bipolar disorders
    • Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated)
  581. Vancomycin General information
    Section
    Watch group antibiotics
    • Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)
    • Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
    • Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection
  582. Varenicline General information
    Section
    Medicines for disorders due to psychoactive substance use
    • Oral > Solid: 0.5 mg; 1 mg
  583. Varicella vaccine General information
    Section
    Recommendations for immunization programmes with certain characteristics
    • All vaccines should comply with the WHO requirements for biological substances.
  584. Vecuronium General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 10 mg in vial powder for injection (vecuronium bromide)
    Indications
  585. Verapamil General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 2.5 mg per mL in 2 mL ampoule (hydrochloride)
    • Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)
    Section
    Antianginal medicines
    • Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)
    Indications
  586. Vinorelbine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
    • Oral > Solid: 20 mg; 30 mg; 80 mg
  587. Voriconazole General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 200 mg in vial powder for injection
    • Oral > Liquid: 40 mg per mL powder for oral liquid
    • Oral > Solid: 50 mg tablet; 200 mg tablet
  588. Warfarin General information
    Section
    Medicines affecting coagulation
    • Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt)
  589. Water for injection General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Miscellaneous
    • Parenteral > General injections > unspecified: 2 mL ampoule; 5 mL ampoule; 10 mL ampoule
  590. Whole blood General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
  591. Xylometazoline General information
    Section
    Ear, nose and throat medicines [c]
    • Local > Nasal > Spray: 0.05% w/v equivalent to 0.5 mg per mL
    Indications
  592. Yellow fever vaccine General information
    Section
    Recommendations for certain regions
    • All vaccines should comply with the WHO requirements for biological substances.
  593. Zidovudine General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion injection
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 250 mg capsule; 300 mg tablet
  594. Zinc sulfate General information
    Section
    Medicines for diarrhoea
    • Oral > Solid: 20 mg
    Indications
  595. Zoledronic acid General information
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle
  596. Zuclopenthixol decanoate General information
    Section
    Medicines for psychotic disorders